Agilent Technologies, Inc. $A Position Lowered by Horizon Investments LLC

Key Points

• Horizon Investments LLC significantly reduced its stake in Agilent Technologies by 80.5%, holding just 4,129 shares after selling 17,069 in the first quarter.
• Agilent Technologies reported a quarterly revenue of $1.67 billion, beating estimates and showing a 6.0% year-over-year increase.
• The company recently declared a quarterly dividend of $0.248, marking an annualized yield of 0.8% with a payout ratio of 24.44%.

Horizon Investments LLC lessened its holdings in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 80.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,129 shares of the medical research company's stock after selling 17,069 shares during the quarter. Horizon Investments LLC's holdings in Agilent Technologies were worth $482,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in A. Brighton Jones LLC lifted its stake in shares of Agilent Technologies by 6.1% during the 4th quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company's stock worth $626,000 after purchasing an additional 270 shares during the period. Townsquare Capital LLC lifted its stake in shares of Agilent Technologies by 33.5% during the 4th quarter. Townsquare Capital LLC now owns 2,593 shares of the medical research company's stock worth $348,000 after purchasing an additional 651 shares during the period. Guggenheim Capital LLC raised its position in shares of Agilent Technologies by 3.5% in the 4th quarter. Guggenheim Capital LLC now owns 9,804 shares of the medical research company's stock worth $1,317,000 after buying an additional 332 shares during the period. NewEdge Advisors LLC raised its position in shares of Agilent Technologies by 1.3% in the 4th quarter. NewEdge Advisors LLC now owns 19,123 shares of the medical research company's stock worth $2,569,000 after buying an additional 253 shares during the period. Finally, Commerce Bank raised its position in shares of Agilent Technologies by 2.3% in the 4th quarter. Commerce Bank now owns 33,410 shares of the medical research company's stock worth $4,488,000 after buying an additional 746 shares during the period.

Agilent Technologies Stock Up 3.7%

NYSE A traded up $4.3420 during trading hours on Friday, hitting $121.4920. The company had a trading volume of 1,290,972 shares, compared to its average volume of 1,284,543. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $153.84. The company has a market capitalization of $34.51 billion, a price-to-earnings ratio of 30.00, a P/E/G ratio of 3.69 and a beta of 1.22. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.09 and a quick ratio of 1.60. The firm's 50 day moving average is $117.88 and its 200 day moving average is $117.26.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings results on Wednesday, May 28th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.05. Agilent Technologies had a return on equity of 25.92% and a net margin of 17.59%.The firm had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.63 billion. During the same period in the prior year, the firm earned $1.22 EPS. The firm's quarterly revenue was up 6.0% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.540-5.610 EPS. Q3 2025 guidance at 1.350-1.370 EPS. Sell-side analysts anticipate that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on A. TD Cowen increased their target price on Agilent Technologies to $150.00 and gave the stock a "buy" rating in a research report on Thursday, May 29th. JPMorgan Chase & Co. cut their target price on Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating on the stock in a research report on Thursday, May 29th. Robert W. Baird cut their target price on Agilent Technologies from $159.00 to $140.00 and set an "outperform" rating on the stock in a research report on Thursday, May 22nd. Barclays increased their target price on Agilent Technologies from $115.00 to $125.00 and gave the stock an "equal weight" rating in a research report on Tuesday, June 24th. Finally, UBS Group cut their target price on Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating on the stock in a research report on Thursday, May 29th. Seven research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $139.77.

Insider Buying and Selling at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the firm's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total transaction of $177,099.52. Following the completion of the sale, the chief executive officer directly owned 37,448 shares in the company, valued at $4,397,893.12. This trade represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.